Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.
How this was made
The 30-second read
Why it matters
RAPIDe-3 is a pivotal Phase 3 readout published in The Lancet, reporting faster symptom relief and complete resolution versus placebo, with no safety signals, while NDA and MAA are under regulatory review.
Market read
Traders may reassess approval odds and near-to-medium-term biotech sentiment as pivotal efficacy and safety results are published, while regulatory timelines remain the next key catalyst.
What to watch
The article does not provide effect-size magnitude beyond time-to-event figures, nor does it discuss comparative positioning versus existing on-demand therapies or payer/access dynamics that could affect commercial uptake post-approval.
Background
Pharvaris is developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE), with deucrictibant IR targeting on-demand treatment of acute attacks.
Ticker impact
Pharvaris reported RAPIDe-3 Phase 3 results in The Lancet, showing faster time to symptom relief and complete resolution versus placebo, plus a well-tolerated safety profile.
Likely upward bias as investors price higher approval odds and de-risk the on-demand HAE program ahead of the FDA PDUFA date.
The article discloses primary and all 11 secondary endpoints met with high statistical significance, with no safety signals, and reiterates ongoing NDA/MAA review with a defined FDA action date.
Market effects
Strengthens the competitive narrative for oral bradykinin B2 receptor antagonists in hereditary angioedema, potentially raising investor attention to similar late-stage programs.
Limited direct regional impact; EMA review underway alongside FDA review.
Global Phase 3 design and publication in The Lancet may broaden clinician and patient awareness internationally, supporting long-term demand expectations if approved.
Counterpoint
Even with positive Phase 3 data, approval timing and label details remain uncertain, and investors may already be positioned for efficacy given prior RAPIDe-1/ongoing RAPIDe-2.
Key entities
- companyPharvaris
Late-stage biopharmaceutical developing oral bradykinin B2 receptor antagonists; subject of the press release.
- drug_programdeucrictibant immediate-release (IR)
Orally administered bradykinin B2 receptor antagonist capsule evaluated for on-demand treatment of HAE attacks.
- clinical_trialRAPIDe-3
Phase 3 global randomized double-blind placebo-controlled crossover study of deucrictibant IR in adolescents and adults.
- regulatorFDA
Regulatory authority reviewing the NDA, with a PDUFA target action date of April 23, 2027.
- regulatorEMA
Regulatory authority reviewing the MAA for on-demand treatment of HAE attacks.
